Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally.
The company has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime , Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Market Cap(M$): 165
52 Week High: 1.67$
52 Week Low: 0.53$
Forward PE: -6.11
2015-12-22, Oppenheimer, Outperform
2016-02-19, Chardan Capital, Buy
2016-09-23, Ladenburg Thalmann, Buy
2019-03-18, Raymond James, Outperform
Analyzing the stock from a technical perspective, we have these conclusions:
The stock is in an uptrend in the short-term and is expected to continue this trend for the next few days.
short-term momentum is positive and medium-term momentum looks positive based on technical momentum indicators for the perspective time periods.
Oversold/Overbought: the stock is overbought in the short term and is overbought in the medium term.
the recent trigger to buy/sell based on technical triggers is to buy.